Publications in collaboration with researchers from Hospital Universitario Virgen del Rocío (89)

2024

  1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

  2. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

    American Journal of Hematology

  3. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  4. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

  5. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer, Vol. 130, Núm. 20, pp. 3436-3451

  6. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

    Annals of Hematology, Vol. 103, Núm. 2, pp. 451-461

2023

  1. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

    Blood Cancer Journal, Vol. 13, Núm. 1

  2. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  3. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

    Haematologica

  4. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

    Cancers, Vol. 15, Núm. 2

  5. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 4

  6. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

  7. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

    European Journal of Haematology, Vol. 111, Núm. 3, pp. 485-490

  8. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679

  9. Spanish registry of thrombotic thrombocytopenic purpura (REPTT): Data evidence and new developments

    Transfusion and Apheresis Science, Vol. 62, Núm. 3

2022

  1. Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry

    Leukemia Research, Vol. 115

  2. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

    Cancers, Vol. 14, Núm. 9

  3. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

  4. Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era

    Annals of Hematology, Vol. 101, Núm. 1, pp. 59-67

  5. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

    Blood Advances, Vol. 6, Núm. 24, pp. 6219-6227